Given the increasing number of licensing deals and the expected approval of multiple: By Roots:

Roots Analysis has done a detailed study on Cell Encapsulationv: Focus on Therapeutics and Technologies, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 500+ page report, which features 170+ figures and 395+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/cell-encapsulation-focus-on-therapeutics-and-technologies-2019-2030-/249.html

Key Market Insights
 Presently, over 45 encapsulated cell therapies and encapsulation technologies are being evaluated across different phases of development by stakeholders across the world
 Ongoing therapy development programs are evaluating different types of cells, encapsulated in a wide range of biocompatible materials, aiming to offer viable and effective treatment options for various diseases
 In fact, majority of the product candidates are being developed for the treatment of metabolic disorders, primarily diabetes; big pharma are driving a significant proportion of research and development activity
 Clinical research in this field is growing at a fast pace; encapsulated therapy products are evaluating a number of pre-marketing end points to validate safety / efficacy
 Over the years, more than 3,000 patents have been granted / filed related to cell encapsulation technologies, demonstrating the heightened pace of research in this domain
 Foreseeing a lucrative future, several private and public investors have made capital investments worth approximately USD 1 billion, across over 100 funding instances, since 2013
 Growth in partnership activity reflects the rising interest of stakeholders in this domain; over 70% of deals have been inked related to therapies for metabolic disorders,

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com

Leave a Reply

Your email address will not be published. Required fields are marked *